HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phthalates comment period

This article was originally published in The Rose Sheet

Executive Summary

California Office of Environmental Health Hazard Assessment extends public comment period to Aug. 26 for butyl benzyl phthalate, di-n-butyl phthalate, di-n-hexyl phthalate and di-isodecyl phthalate, which are under consideration for possible listing as carcinogens under Proposition 65, agency announces. Phthalates also will be addressed by the California Senate next month when it considers AB 2012, which seeks to ban the manufacture and distribution of personal care products formulated with the chemicals. Bill passed the state's Senate Health and Human Services Committee June 30 (1"The Rose Sheet" July 5, 2004, p. 5)...

You may also be interested in...

Proposed Calif. Phthalates Ban Revived; Headed To Senate Floor

Legislation introduced by California Assembly member Judy Chu (D-49th) seeking to prohibit the manufacture or distribution of personal care products containing phthalates likely will be addressed on the California State Senate floor in August, according to Chu staffers

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts